The Clinical Trial Process: A Step-by-Step Guide for Patients

The clinical trial process is the system through which new medical treatments move from laboratory discovery to FDA-approved therapies available to patients. Every drug, vaccine, medical device, and biologic treatment used in modern medicine went through this process before reaching the market.

For patients considering trial participation, understanding what happens at each stage — and what to expect as a participant — removes much of the uncertainty and helps you make informed decisions about your care.

Key Takeaways

The full clinical trial process from discovery to FDA approval takes an average of 10-15 years and costs approximately $1-2 billion per approved drug
Clinical trials progress through 4 phases, each with a specific purpose, size, and duration
Only about 12% of drugs that enter Phase I trials eventually receive FDA approval
Patient participation is voluntary at every stage — you can withdraw at any time without affecting your regular care
Many of the newest treatments for cancer, rare diseases, and neurological conditions are available only through clinical trials

How Does the Clinical Trial Process Work?

Preclinical Research (3-6 years before human trials)

Before any treatment is tested in people, it undergoes extensive laboratory and animal studies:

Discovery: Researchers identify a potential drug target — a protein, gene, or pathway involved in a disease
Lab testing: The compound is tested in cell cultures to evaluate its biological activity
Animal studies: Safety, dosing, and toxicity are evaluated in animal models
IND application: The sponsor files an Investigational New Drug (IND) application with the FDA, providing all preclinical data and a proposed plan for human testing

Only compounds that demonstrate both safety and potential efficacy in preclinical studies advance to human trials. The FDA reviews the IND within 30 days and either allows the trial to proceed or places it on clinical hold.

Phase I: Safety and Dosing (6-12 months)

Purpose: Determine whether the treatment is safe for humans and identify the right dose.

| Detail | Phase I | |--------|---------| | Participants | 20-100 healthy volunteers or patients | | Duration | 6-12 months | | Primary goal | Safety, tolerability, pharmacokinetics | | Success rate | ~63% advance to Phase II |

What happens: Participants receive increasing doses of the treatment while researchers monitor for side effects, measure how the drug is absorbed and metabolized, and determine the maximum tolerated dose. In oncology trials, Phase I participants are typically patients with advanced cancer who have exhausted standard treatments.

What to expect as a participant: Frequent monitoring visits (sometimes daily), extensive bloodwork, ECGs, and detailed reporting of any symptoms. Phase I trials often take place at specialized research centers.

Phase II: Efficacy and Side Effects (1-3 years)

Purpose: Determine whether the treatment actually works against the target disease.

| Detail | Phase II | |--------|----------| | Participants | 100-300 patients with the target condition | | Duration | 1-3 years | | Primary goal | Efficacy, optimal dosing, side effect profile | | Success rate | ~31% advance to Phase III |

What happens: Patients with the specific condition receive the treatment at doses identified in Phase I. Researchers measure disease response — tumor shrinkage, biomarker changes, symptom improvement — and document all adverse events. Phase II trials may be randomized (comparing the drug to a placebo or standard treatment) or single-arm (everyone receives the experimental treatment).

What to expect as a participant: Regular clinic visits every 2-4 weeks, imaging scans (CT, MRI, PET), blood tests, and quality-of-life questionnaires. You'll have close contact with the research team and detailed informed consent about known risks.

Phase III: Comparison and Confirmation (2-4 years)

Purpose: Confirm the treatment works better (or no worse) than the current standard of care.

| Detail | Phase III | |--------|-----------| | Participants | 300-3,000+ patients | | Duration | 2-4 years | | Primary goal | Confirm efficacy, monitor adverse reactions, compare to standard care | | Success rate | ~58% lead to FDA approval |

What happens: Phase III trials are typically randomized, double-blind, and controlled — meaning patients are randomly assigned to receive either the new treatment or the current standard (or placebo), and neither the patient nor the doctor knows which group they're in until the study ends. This design eliminates bias and produces the most reliable evidence.

A Data Safety Monitoring Board (DSMB) reviews results periodically during the trial. If the new treatment shows clear superiority, the DSMB may recommend stopping the trial early so all participants can receive it. Conversely, if safety concerns emerge, the trial may be halted.

What to expect as a participant: Visits every 4-8 weeks at a hospital or clinic near you (Phase III trials typically have multiple sites). Less frequent monitoring than Phase I/II, but longer overall commitment. You may or may not know which treatment you're receiving until the study concludes.

FDA Review and Approval (6-24 months)

After successful Phase III results, the sponsor submits a New Drug Application (NDA) or Biologics License Application (BLA) to the FDA:

Standard review: 10-12 months
Priority review: 6-8 months (for treatments addressing serious conditions)
Accelerated approval: Based on surrogate endpoints for serious conditions with unmet need
Breakthrough therapy designation: Expedited development for drugs showing substantial improvement over existing treatments

The FDA reviews all clinical data, manufacturing processes, and proposed labeling. An advisory committee of independent experts may also weigh in. If approved, the treatment becomes available by prescription.

Phase IV: Post-Market Surveillance (ongoing)

Purpose: Monitor long-term safety and effectiveness after FDA approval.

Phase IV studies track the treatment in real-world populations much larger and more diverse than clinical trial participants. These studies can identify rare side effects that weren't detected in smaller trials, evaluate the drug's performance in specific subpopulations, and confirm long-term benefits.

Clinical Trial Timeline: How Long Does the Whole Process Take?

| Stage | Duration | Cumulative | |-------|----------|-----------| | Preclinical | 3-6 years | 3-6 years | | Phase I | 6-12 months | 4-7 years | | Phase II | 1-3 years | 5-10 years | | Phase III | 2-4 years | 7-14 years | | FDA Review | 6-24 months | 8-15 years |

Accelerated pathways can compress this timeline significantly. The COVID-19 vaccines went from discovery to Emergency Use Authorization in under 12 months — though this was exceptional and involved parallel processing of stages that are normally sequential.

What Patients Should Know Before Joining

Your Rights as a Participant

You will receive detailed informed consent before enrolling
You can leave the trial at any time for any reason
Your regular medical care will not be affected by your decision
Your privacy is protected by HIPAA and study-specific confidentiality protocols
You'll have direct access to the research team for questions or concerns

Costs and Compensation

Study treatment and study-related tests are free
Routine medical care may still be billed to your insurance
Many trials offer compensation for time and travel
Your insurance company cannot increase premiums or deny coverage because you participate in a trial

Finding the Right Trial

Not all trials are equal — the right trial depends on your specific diagnosis, stage, prior treatments, and personal preferences. Resources for finding trials:

Health Pioneer's clinical trial matching tool — AI-powered matching against 450,000+ active studies
ClinicalTrials.gov — the NIH public registry
Your oncologist or specialist — especially at NCI-designated cancer centers
Disease-specific advocacy organizations

For a deeper look at how AI is transforming trial discovery, read our guide on clinical trial matching.

Frequently Asked Questions

How are clinical trial participants selected?

Each trial defines specific eligibility criteria based on diagnosis, stage, prior treatments, age, and overall health. These criteria exist to ensure participant safety and produce scientifically valid results.

What is a placebo-controlled trial?

A trial where some participants receive the experimental treatment and others receive a placebo (inactive substance). Importantly, many modern trials compare the new treatment to the current standard of care rather than a placebo — so all participants receive active treatment.

Can I still see my regular doctor during a trial?

Yes. Clinical trial participation supplements your regular care. The research team coordinates with your physician to ensure comprehensive treatment.

What happens if the trial drug doesn't work for me?

If you don't respond to the treatment, or if side effects are unacceptable, you can discontinue. The research team will help you transition back to standard care or explore other options, including other clinical trials or emerging therapies.

The Importance of Clinical Trial Participation

Clinical trials depend on volunteer participants. Without them, no new treatments can reach patients. Yet only about 5% of adult cancer patients participate in clinical trials, creating a major bottleneck in medical progress.

Common barriers — lack of awareness, fear of placebos, travel burden, and mistrust — are addressable. AI-powered trial matching is making discovery easier. Decentralized trial designs are reducing travel requirements. And platforms like Health Pioneer are providing plain-language education to help patients make confident decisions.

Every breakthrough treatment that exists today — from immunotherapy to mRNA vaccines to gene therapy — reached patients because earlier participants volunteered for clinical trials. Your participation could do the same for future patients.

Sources

Wouters, O.J., et al. (2020). "Estimated research and development investment needed to bring a new medicine to market, 2009-2018." JAMA, 323(9), 844-853. doi:10.1001/jama.2020.1166
Hay, M., et al. (2014). "Clinical development success rates for investigational drugs." Nature Biotechnology, 32(1), 40-51. doi:10.1038/nbt.2786
Wong, C.H., et al. (2019). "Estimation of clinical trial success rates and related parameters." Biostatistics, 20(2), 273-286. doi:10.1093/biostatistics/kxq046
FDA. "The Drug Development Process." fda.gov
Unger, J.M., et al. (2019). "Trends in clinical trial participation." Journal of Clinical Oncology, 37(15_suppl), 6500. doi:10.1200/JCO.2019.37.15_suppl.6500

Published April 4, 2026.